The Sorin Group (MIL:SRN), a world leader in technologies for the
treatment of cardiovascular diseases, announces the successful implant
of its first uniquely-designed heart valve suitable for percutaneous
procedures. The implant was performed by Prof. Axel Haverich and his
team at Medizinische Hochschule in Hannover, Germany. The 78-year-old
patient, who was suffering from aortic heart valve stenosis, has
already left intensive care and is recovering normally, according to
his physicians.
"The ease with which the valve was implanted, without any use of
sutures, allows for significant reduction in procedure time and
corresponding patient risk," commented Prof. Haverich.
Thanks to its unique design - in which the securing structure is
independent from the valve-supporting system -, the valve is
self-securing and is in no way put under any stress, therefore
overcoming the primary defects of other minimally-invasive valves
currently being tested.
The success behind Sorin's heart valve lies in the Group's
in-house competencies in stent research and development as well as its
historic prominence in heart-valve development and production. The
characteristics of the securing stent and the flexibility of the valve
are designed to ensure optimal sealing and prevent perivalvular
leakage, breaking new ground in the evolution of heart valves.
The particular biological valve itself used as part of "Sorin's
Percutaneous Heart Valve Project" has a proven track record for its
hemodynamic profile, reliability and durability over the past two
decades and has never had any structural failures since it has been in
use. Sorin is the only company in the world to use a heart valve that
has been proven and accepted by the medical community worldwide in
this particular context.
"Only the Sorin Group has the in-house know-how and strong
tradition in research and development to create such a unique heart
valve," said Drago Cerchiari, Sorin Group Chief Executive Officer. "We
look forward to continuing to achieve our ultimate goal of offering
high-quality, less invasive, life-saving medical technology and
procedures across the globe."
About the Sorin Group
The Sorin Group (Bloomberg: SRN.IM; Reuters: SORN.MI), a world
leader in the development of medical technologies for cardiac surgery,
offers innovative therapies for cardiac rhythm dysfunctions,
interventional cardiology and the treatment of chronic kidney
diseases. The Sorin Group includes: Dideco, CarboMedics, Inc., COBE
Cardiovascular, Inc., Stockert, Mitroflow, ELA Medical, Inc., Sorin
Biomedica, Bellco and Soludia. It has more than 4,500 employees
working at facilities in more than 80 countries throughout the world
to serve over 5,000 public and private treatment centers. For more
information, please visit: www.sorin.com
